Related Experiment Video
Updated: Jan 12, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Pulmonary function impairment and its relationship with target therapy response in patients with pulmonary arterial
Xia Xu1, Mengshuang Xie1, Haijun Li1
1Department of Geriatric Medicine & Laboratory of Gerontology and Anti-Aging Research, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Introduction:
Patients with pulmonary arterial hypertension (PAH) exhibit exertional dyspnea and decreased exercise capacity, which are not solely attributable to right heart dysfunction. Numerous studies have aimed to elucidate pulmonary function in PH patients and its correlation with disease severity and prognosis; however, the findings remain inconsistent. The impairment of ventilation and diffusion function may partially account for the occurrence of exertional dyspnea in PAH patients.
Methods:
This was a single-center prospective observational study. Pulmonary function tests, right heart catheterization, and four-strata risk status stratification were performed in PAH patients. The PAH patients were followed up for 12 months.
Results:
A total of 181 PAH patients were enrolled in the study, comprising 62 with idiopathic pulmonary arterial hypertension (IPAH) and heritable PAH (HPAH), 69 with PAH associated with congenital heart disease (CHD-PAH), and 50 with PAH associated with connective tissue disease (CTD-PAH). Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), single-breath diffusion capacity for carbon monoxide (DLCO), DLCO% predicted (% pred), and reactance at 5 Hz (X5) were significantly reduced, while residual volume (RV)% pred increased in PAH patients. CHD-PAH exhibited more pronounced ventilation impairment. Six-minute walking distance (6MWD) demonstrated a positive correlation with FEV1 (r = 0.353, p < 0.01) and FVC (r = 0.373, p < 0.01), respectively. A total of 104 patients finished the follow-up. Patients exhibiting FVC% pred values below 82% demonstrated a diminished response to PAH-targeted therapy (OR = 10.553, p = 0.000, 95% CI: 2.580-43.165).
Conclusion:
PAH patients exhibited impairment in both ventilation and diffusion capacity, while patients with diverse etiologies demonstrated distinct characteristics. FVC and FEV1 were positively correlated with 6MWD, respectively. PAH patients with FVC% pred values below 82% demonstrated a diminished response to PAH-targeted therapy.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

